Improving the ACA for kidney patients
While the ACA provides many benefits for people at risk of and with kidney disease there are still improvements that need to be made to ensure people with kidney disease, including those on dialysis and with a transplant, have access to the care they need. We need to ensure plans do not charge higher out-of-pocket costs for care and medications, restrict access to necessary healthcare providers and services, and limit benefits because of health conditions. NKF has been successful in overturning many discriminatory practices in the first two years of the ACA. However, there is much work left to be done and NKF continues to work with federal and state governments to ensure kidney patients have better access to health insurance and healthcare services.
Latest ACA and Health Insurance Updates
3/6/2020 — NKF submitted comments on the CY2021 Medicare Advantage Advance Notice. We highlight the importance of offering ESRD patients more insurance coverage options. Read the comments here.[Link to Medicare Advantage_NKF_FINAL PDF]
3/6/2020 — NKF joined the MAPRx Coalition to comment on the CY2021 Medicare Advantage Advance Notice. The comments urge CMS to not inhibit access to branded medications when clinically appropriate. Read the comments here.[Link to MAPRx - Advance Notice comments]
3/6/2020 — NKF's Coalition for Kidney Health submitted comments on the CY2021 Medicare Advance Notice in support of the adoption of the Kidney Health Evaluation Measure in the Medicare Advantage Star Ratings. Read the comments here.[ Link to MA Advance Notice_Coalition for Kidney Health_Final]
10/16/2019 — The National Kidney Foundation was pleased to join with Medicare Access for Patients Rx (MapRx) to voice our support for provisions of TITLE III of H.R. 3, the Lower Drug Costs Now Act of 2019 that would cap Medicare Part D out-of-pocket (OOP) costs. The letter notes that the cap should be implemented as soon as possible, highlights the need for increased oversight over the benefit, and specifies that more should be done to strengthen the Part D program. Read the letter here
8/13/19 — NKF signed onto an I am Essential coalition letter expressing concern with proposed revisions to the regulations implementing § 1557 of the Affordable Care Act (ACA) that would undermine critical patient protections guaranteed by the ACA. Read the letter here
7/25/19 — The National Kidney Foundation (NKF) signed on to Medicare Access for Patients Rx (MAPRx) Coalition letter to Senate Finance Committee Chairman Chuck Grassley and Ranking Member Ron Wyden asking the committee to strengthen the out of pocket (OOP) cap provisions in the Senate Finance legislation, The Prescription Drug Pricing Reduction Act of 2019. Read the letter here
6/6/19 — The National Kidney Foundation (NKF) was pleased to support the National Health Council (NHC)'s comments to the House of Representatives highlighting the need for reforms to the Medicare Part D prescription drug program that would make out-of-pocket costs more manageable for part D beneficiaries. Read the letter here
6/6/19— The National Kidney Foundation (NKF) was one of many members of the Medicare Access for Patients Rx (MAPRx) Coalition that signed on to a letter to the House of Representatives in support of improvements to the Medicare Part D prescription drug program. Read the letter here
5/15/19— The National Kidney Foundation (NKF) endorsed H.R. 1386, the Expand Navigator's Resources for Outreach, Learning, and Longevity (ENROLL) Act of 2019. The ENROLL Act restores essential funding for education and outreach that assist patients with understanding and enrolling in federal exchange plans. Provisions of the ENROLL Act were passed by the House of Representatives on May 16 as part of H.R. 987, the Strengthening Health Care and Lowering Prescription Drug Costs Act. Read NKF's letters of support here and here.
9/5/18— National Kidney Foundation's (NKF) joint statement regarding Senate Healthcare legislation’s coverage of pre-existing conditions. Read the full statement (pdf)
7/16/18 - National Kidney Foundation's (NKF) joint statement regarding the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket (OOP) Costs. Read the full statement (pdf).
11/27/17 — National Kidney Foundation's (NKF) statement on the proposed Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters (NBPP) for 2019. Read More (pdf)
10/13/17 — National Kidney Foundation's (NKF) statement on President Trump's Executive Order to Amend the Affordable Care Act. Read More
9/22/17 — National Kidney Foundation's (NKF) statement on the Senate Graham-Cassidy healthcare proposal. Read More
4/28/17 — As lawmakers consider amendments to the American Health Care Act (AHCA), the National Kidney Foundation has significant concerns for millions of Americans affected by chronic diseases. Read more (pdf)
3/22/17 — As lawmakers consider repealing and replacing the Affordable Care Act, the National Kidney Foundation (NKF) calls on Congress and the Administration to ensure that individuals with, and at risk for, kidney disease have meaningful access to affordable healthcare and insurance coverage. Read more (pdf)
7/27/16 — NKF wrote to the Idaho Department of Insurance supporting changes in the proposed "Rule to Implement the NAIC Medicare Supplement Insurance Minimum Standards Model Act." Read the final comments (pdf).
2/1/16 — NKF submitted comments to the Idaho State Office of the Insurance Commission regarding discriminatory plan designs by several insurers for end-stage renal disease (ESRD) patients. Read the full comments (pdf).
1/26/16 — NKF submitted comments to the Washington State Office of the Insurance Commission regarding discriminatory plan designs by several insurers for end-stage renal disease (ESRD) patients. Read the full comments (pdf).
1/15/16 — NKF submitted comments to the Department of Health and Human Services on the Draft 2017 Letter to Issuers in the Federally-facilitated Marketplaces. Read the full comments (pdf).
2015 (click to expand)